| Bioactivity | α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Glucosidase-IN-21 shows anti-diabetic activity[1]. |
| In Vivo | α-Glucosidase-IN-21 (Compound 2B; 10 and 20 mg/kg; p.o.; daily, for 4 weeks) has anti-diabetic activity in Streptozocin (HY-13753)-induced diabetic rats[1].α-Glucosidase-IN-21 (10 and 20 mg/kg; p.o.; once) significantly decreases the serum glucose level after the administration of glucose (3 g/kg, oral) in rats[1].α-Glucosidase-IN-21 (2000 mg/kg; p.o.; daily, for 2 weeks) demonstrates no mortality in mice[1]. Animal Model: |
| Name | α-Glucosidase-IN-21 |
| CAS | 321686-01-5 |
| Formula | C24H23NO2S |
| Molar Mass | 389.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mehmood R, et al. Synthesis of Novel 2, 3-Dihydro-1, 5-Benzothiazepines as α-Glucosidase Inhibitors: In Vitro, In Vivo, Kinetic, SAR, Molecular Docking, and QSAR Studies. ACS Omega, 2022 Aug 17. |
α-Glucosidase-IN-21
CAS: 321686-01-5 F: C24H23NO2S W: 389.51
α-Glucosidase-IN-21 (Compound 2B) is a potent, orally active α-glucosidase inhibitor with an IC50 of 2.62 μM. α-Gluc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.